Evidence map›Paper›PMID 40770613›Full record

ArticleBMC primary care2025

Adaptation and pilot implementation of a hereditary cancer risk-assessment tool for primary care.

Sukh Makhnoon, Anoop Gurram, Eyad Alrabbat, Tiwatope Ibidapo, Ying Ma, Emanuel Villa, Michael E Bowen, Sayoni Lahiri, Celette Sugg Skinner, Sara Pirzadeh-Miller and 1 more

Abstract read
In one paragraph

Article in BMC primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sukh MakhnoonPeter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA. sukh.makhnoon@utsouthwestern.edu.
Anoop GurramMedical School, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Eyad AlrabbatPeter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
Tiwatope IbidapoPeter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
Ying MaPeter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
Emanuel VillaPeter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
Michael E BowenPeter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
Sayoni LahiriCancer Genetics Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Celette Sugg SkinnerPeter O'Donnell School of Public Health, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.
Sara Pirzadeh-MillerCancer Genetics Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Steven LeachDivision of General Internal Medicine, University of Texas Southwestern, Dallas, TX, USA.

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MELANIE H. COBB · 2010 to 2026
$53.7M
NCI NIH HHS 3P30 CA 142543-10S3NCI NIH HHS P30 CA142543
6 · The paper itself

Abstract

backgroundFamily history-based risk assessment for hereditary breast and ovarian cancer is guideline-recommended but clinical implementation remains limited. This is likely, in part, because it adds to the limited time primary care providers (PCPs) have to implement all guideline-recommended care.

methodsWe adapted Family History Screening 7 (or FHS7), designed for administration by a PCP, for self-report by primary care patients. We used the Framework for Reporting Adaptation and Modifications to Evidence-based Implementation Strategies (FRAME) to guide the modifications. We conducted a pilot feasibility study of hereditary prevention program using the adapted risk-assessment tool and report results from the first year of the program (February 2023-March 2024).

resultsFeedback from clinical stakeholders and our literature review revealed that, while hereditary cancer risk assessment was a priority for the primary care setting, implementation by PCPs was not feasible. We therefore adapted FHS7 for patient self-report by separating double-barreled items and eliminating jargon, resulting in nine items- six with binary (yes/no) and three with numeric responses. Outcomes from pilot implementation of the adapted FHS7 (n=4,355) showed high completion rate (77% completed all items), with greater completion via MyChart than in-person (87% vs. 13%), and higher non-response for the three items with numeric responses compared to the six with binary responses. Overall, positivity rate of the adapted FHS7 was 36%.

conclusionThis paper describes our team's process of adapting the FHS7 questionnaire to retain the core function (evaluating specific family history of cancer information) while adapting to fit the clinical context. Preliminary implementation data suggest high completion rate in the primary care setting.

Indexed as

Breast NeoplasmsMedical History TakingOvarian NeoplasmsPrimary Health CareAdultFeasibility StudiesFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPilot ProjectsRisk AssessmentSelf ReportAdaptationHereditary cancerImplementationRisk assessment

Identifiers

PMID40770613
PMCPMC12326799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.